1
项与 PIKA COVID-19 vaccine(Yisheng Biopharma (Singapore) Pte. Ltd.) 相关的临床试验A Phase II/III, Randomized, Double-blinded Study to Evaluate the Efficacy, Safety and Immunogenicity of a Booster Dose of PIKA Recombinant SARS-CoV-2 Vaccine in Adults Who Received 2 or More Doses of Inactivated Covid-19 Vaccine.
This is a Phase II/III, randomized, double-blinded study in adults ≥ 18 years old who received 2 or more doses of inactivated COVID-19 vaccine to evaluate the efficacy, safety and immunogenicity of a booster dose of PIKA COVID-19 vaccine compared to the comparator inactivated COVID-19 vaccine. Phase II/III will be a competitive enrollment process in all participating countries. Once the target number of subjects is reached, the enrollment in all participating countries in the particular phase will be stopped.
100 项与 PIKA COVID-19 vaccine(Yisheng Biopharma (Singapore) Pte. Ltd.) 相关的临床结果
100 项与 PIKA COVID-19 vaccine(Yisheng Biopharma (Singapore) Pte. Ltd.) 相关的转化医学
100 项与 PIKA COVID-19 vaccine(Yisheng Biopharma (Singapore) Pte. Ltd.) 相关的专利(医药)
100 项与 PIKA COVID-19 vaccine(Yisheng Biopharma (Singapore) Pte. Ltd.) 相关的药物交易